Endometrial ablation plus levonorgestrel-releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding in The Netherlands (MIRA2): a multicentre, open-label, randomised, controlled, superiority trial
Source: View publication →
In women with heavy menstrual bleeding, combining endometrial ablation with a levonorgestrel-releasing intrauterine system (LNG-IUS) significantly reduces the rate of subsequent hysterectomies at 24 months compared to endometrial ablation alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
Endometrial ablation frequently fails in the long term, with 12–25% of women ultimately requiring a hysterectomy due to persistent bleeding or cyclical pain from trapped endometrium. The MIRA2 trial establishes a new paradigm by demonstrating that immediate placement of a levonorgestrel-releasing IUS after ablation successfully mitigates this risk, offering a highly effective, uterus-sparing standard of care for heavy menstrual bleeding.
Historical Context
Since the introduction of non-resectoscopic endometrial ablation in the 1990s, the procedure has been a favored minimally invasive alternative to hysterectomy. However, a major clinical challenge has been the significant proportion of patients who eventually require hysterectomy due to endometrial regrowth or trapped blood causing severe cyclical pain. While retrospective data suggested that adding an LNG-IUS could suppress this regrowth and prevent failure, the MIRA2 trial provides the first rigorous, large-scale randomized evidence to support this dual-therapy approach.
Guided Discussion
High-yield insights from every perspective
How does the combined mechanism of endometrial ablation and the LNG-IUS work synergistically to treat heavy menstrual bleeding compared to ablation alone?
Key Response
Ablation destroys the basal layer of the endometrium, while the LNG-IUS provides profound local progestin-induced atrophy of any remaining endometrial islands, preventing the regrowth that often leads to ablation failure and recurrent bleeding.
When counseling a patient with HMB about to undergo endometrial ablation, how should the MIRA2 data change your preoperative consent and management plan?
Key Response
Residents should incorporate this data into shared decision-making, offering concurrent LNG-IUS insertion at the time of ablation as a more definitive fertility-sparing option to significantly lower the patient's risk of needing a subsequent hysterectomy within the next two years.
Given that endometrial ablation alters the uterine cavity architecture by causing synechiae, what are the technical considerations and long-term surveillance challenges of placing an LNG-IUS immediately post-ablation?
Key Response
Placing the IUS immediately avoids the impossibility of inserting it later due to scarring. However, ultrasound surveillance for misplaced devices or evaluating future post-menopausal bleeding becomes highly complex in a scarred, device-occupied cavity.
While the MIRA2 trial shows a reduction in hysterectomies at 24 months, how must we weigh the surgical benefits against the re-introduction of hormonal side effects for patients in routine practice?
Key Response
Attendings must balance the surgical benefit of avoiding hysterectomy with the fact that adding an LNG-IUS introduces systemic progestin side effects (mood changes, bloating) to a population that might have chosen ablation specifically to avoid ongoing medical or hormonal management.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MIRA2 trial was an open-label superiority trial. How does the lack of a sham IUS control potentially bias the primary outcome of subsequent hysterectomy?
Key Response
Hysterectomy is often a subjective, patient-and-provider-driven decision for refractory symptoms. Without blinding, patients and providers in the ablation-alone arm might have a lower threshold to proceed to hysterectomy, potentially inflating the apparent superiority of the combined intervention.
As a peer reviewer, how would you evaluate the choice of a 24-month follow-up period for the primary outcome of hysterectomy in an endometrial ablation trial?
Key Response
Ablation failures often peak between 2 and 5 years due to delayed endometrial regrowth or post-ablation tubal sterilization syndrome. A 24-month endpoint captures early failures but could miss late-onset complications, thus inadequately representing the true long-term success curve of the combination therapy.
Current ACOG and NICE guidelines recommend LNG-IUS or ablation as separate, often sequential, treatment pathways for HMB. Based on MIRA2, should guidelines be updated to recommend routine concurrent LNG-IUS placement with ablation?
Key Response
MIRA2 provides Level I evidence that combination therapy reduces hysterectomy. However, guideline committees must determine if this combination should become a new standalone tier in the HMB algorithm, carefully balancing the increased efficacy against the added healthcare costs and hormonal side effects before issuing a strong recommendation for universal concurrent placement.
Clinical Landscape
Noteworthy Related Trials
Hurskainen Trial
Tested
Levonorgestrel-releasing intrauterine system (LNG-IUS)
Population
Women with heavy menstrual bleeding awaiting hysterectomy
Comparator
Hysterectomy
Endpoint
Health-related quality of life (EQ-5D) at 12 months
ECLIPSE Trial
Tested
Levonorgestrel-releasing intrauterine system (LNG-IUS)
Population
Women with heavy menstrual bleeding
Comparator
Standard medical therapy
Endpoint
Patient-reported Menorrhagia Multi-Attribute Scale (MMAS) score over 2 years
MIRA Trial
Tested
Levonorgestrel-releasing intrauterine system (LNG-IUS)
Population
Women with heavy menstrual bleeding
Comparator
Bipolar radiofrequency endometrial ablation
Endpoint
Menstrual blood loss measured by PBAC score at 24 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis